264 related articles for article (PubMed ID: 33808300)
1. Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario.
Tierens A; Stockley TL; Campbell C; Fulcher J; Leber B; McCready E; Sabatini PJB; Sadikovic B; Schuh AC
Curr Oncol; 2021 Mar; 28(2):1376-1387. PubMed ID: 33808300
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
3. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
Pfeifer H; Cazzaniga G; van der Velden VHJ; Cayuela JM; Schäfer B; Spinelli O; Akiki S; Avigad S; Bendit I; Borg K; Cavé H; Elia L; Reshmi SC; Gerrard G; Hayette S; Hermanson M; Juh A; Jurcek T; Chillón MC; Homburg C; Martinelli G; Kairisto V; Lange T; Lion T; Mueller MC; Pane F; Rai L; Damm-Welk C; Sacha T; Schnittger S; Touloumenidou T; Valerhaugen H; Vandenberghe P; Zuna J; Serve H; Herrmann E; Markovic S; Dongen JJMV; Ottmann OG
Leukemia; 2019 Aug; 33(8):1910-1922. PubMed ID: 30858550
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(8):1-83. PubMed ID: 27099644
[TBL] [Abstract][Full Text] [Related]
5. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
[TBL] [Abstract][Full Text] [Related]
6. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
[TBL] [Abstract][Full Text] [Related]
8. A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
Gupta DG; Varma N; Abdulkadir SA; Sreedharanunni S; Sachdeva MUS; Naseem S; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
Cancer; 2024 Mar; 130(5):713-726. PubMed ID: 37819686
[TBL] [Abstract][Full Text] [Related]
9. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.
Singh J; Gorniak M; Grigoriadis G; Westerman D; McBean M; Venn N; Law T; Sutton R; Morgan S; Fleming S
Cytometry B Clin Cytom; 2022 Mar; 102(2):115-122. PubMed ID: 34806309
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
[TBL] [Abstract][Full Text] [Related]
11. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.
Tang GS; Wu J; Liu M; Chen H; Gong SG; Yang JM; Hu XX; Wang JM
Am J Transl Res; 2015; 7(3):632-9. PubMed ID: 26045902
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia.
Hrabovsky S; Folber F; Horacek JM; Stehlikova O; Jelinkova H; Salek C; Doubek M;
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):743-748. PubMed ID: 30057330
[TBL] [Abstract][Full Text] [Related]
14. Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia.
Thörn I; Botling J; Hermansson M; Lönnerholm G; Sundström C; Rosenquist R; Barbany G
Leuk Res; 2009 Aug; 33(8):1047-54. PubMed ID: 19157547
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
16. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
[TBL] [Abstract][Full Text] [Related]
18. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
[Next] [New Search]
